AIFA OKs 1st gene therapy agst SMA

(ANSA) – ROME, MAR 10 – Italian drugs agency AIFA on
Wednesday approved the first gene therapy against Spinal
Muscular Atrophy (SMA), the most common genetic cause of infant
death.
    The drug, Zolgensma, will be available free of charge on the
national health system for all infants under 13.5 kg in weight,
AIFA said.
    The drug will come into use in a single-administration treatment
starting in April.
    The OK came after a process that began last May.
    Some 40-50 children are estimated to be born in Italy each year
with SMA.
    Makers Novartis has also agreed to make the drug freely
available for clinical trials for children weighing between 13.5
and 21 kg. (ANSA).
   

Previous

Soccer: Ronaldo under fire after Juve exit Champions League (5)

Man, 82, donates kidney to save son in record case

Next

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close